Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,538.70
(
-1.03%
)
US TECH 100
23,411.12
(
-1.31%
)
Dow Jones
45,781.18
(
-0.52%
)
Brent Oil
107.25
(
2.70%
)
Bitcoin
69,589.00
(
-0.44%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: gofishmarko post# 34649

Wednesday, 09/27/2006 5:11:05 PM

Wednesday, September 27, 2006 5:11:05 PM

Post# of 257262
> VPHM – It just occurred to me that the ribavirin interference issue could explain VPHM's assertion that a non-nuke polymerase inhibitor would be preferable.<

Plausible on its face, but VPHM has not offered this answer when asked. Hence, this is not the reason for their assertion about drug classes unless they were being coy by trying to conceal the fact that they got wind of the ACAAC paper.

What do you think?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today